330 related articles for article (PubMed ID: 15140158)
1. Synthetic peptide derived from alpha-fetoprotein inhibits growth of human breast cancer: investigation of the pharmacophore and synthesis optimization.
DeFreest LA; Mesfin FB; Joseph L; McLeod DJ; Stallmer A; Reddy S; Balulad SS; Jacobson HI; Andersen TT; Bennett JA
J Pept Res; 2004 May; 63(5):409-19. PubMed ID: 15140158
[TBL] [Abstract][Full Text] [Related]
2. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors.
Igarashi H; Ito T; Pradhan TK; Mantey SA; Hou W; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2002 Nov; 303(2):445-60. PubMed ID: 12388623
[TBL] [Abstract][Full Text] [Related]
3. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor.
Beyermann M; Fechner K; Furkert J; Krause E; Bienert M
J Med Chem; 1996 Aug; 39(17):3324-30. PubMed ID: 8765516
[TBL] [Abstract][Full Text] [Related]
4. Antiestrogenic and anticancer activities of peptides derived from the active site of alpha-fetoprotein.
Joseph LC; Bennett JA; Kirschner KN; Shields GC; Hughes J; Lostritto N; Jacobson HI; Andersen TT
J Pept Sci; 2009 Apr; 15(4):319-25. PubMed ID: 19189271
[TBL] [Abstract][Full Text] [Related]
5. Anti-prostate cancer and anti-breast cancer activities of two peptides derived from alpha-fetoprotein.
Caceres G; Dauphinee MJ; Eisele LE; MacColl R; Mizejewski GJ
Anticancer Res; 2002; 22(5):2817-20. PubMed ID: 12530002
[TBL] [Abstract][Full Text] [Related]
6. Prevention of N-methyl-N-nitrosourea-induced breast cancer by alpha-fetoprotein (AFP)-derived peptide, a peptide derived from the active site of AFP.
Parikh RR; Gildener-Leapman N; Narendran A; Lin HY; Lemanski N; Bennett JA; Jacobson HI; Andersen TT
Clin Cancer Res; 2005 Dec; 11(23):8512-20. PubMed ID: 16322315
[TBL] [Abstract][Full Text] [Related]
7. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
[TBL] [Abstract][Full Text] [Related]
8. Alpha-fetoprotein derived from a human hepatoma prevents growth of estrogen-dependent human breast cancer xenografts.
Bennett JA; Zhu S; Pagano-Mirarchi A; Kellom TA; Jacobson HI
Clin Cancer Res; 1998 Nov; 4(11):2877-84. PubMed ID: 9829755
[TBL] [Abstract][Full Text] [Related]
9. AFPep: an anti-breast cancer peptide that is orally active.
Bennett JA; DeFreest L; Anaka I; Saadati H; Balulad S; Jacobson HI; Andersen TT
Breast Cancer Res Treat; 2006 Jul; 98(2):133-41. PubMed ID: 16538538
[TBL] [Abstract][Full Text] [Related]
10. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
Stoev S; Cheng LL; Olma A; Klis WA; Manning M; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1999 Mar; 5(3):141-53. PubMed ID: 10323558
[TBL] [Abstract][Full Text] [Related]
11. Minimal-size, constrained corticotropin-releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges.
Rivier J; Lahrichi SL; Gulyas J; Erchegyi J; Koerber SC; Craig AG; Corrigan A; Rivier C; Vale W
J Med Chem; 1998 Jul; 41(14):2614-20. PubMed ID: 9651165
[TBL] [Abstract][Full Text] [Related]
12. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
13. Cyclic peptide interleukin 5 antagonists mimic CD turn recognition epitope for receptor alpha.
Ruchala P; Varadi G; Ishino T; Scibek J; Bhattacharya M; Urbina C; Ryk DV; Uings I; Chaiken I
Biopolymers; 2004 Apr; 73(5):556-68. PubMed ID: 15048779
[TBL] [Abstract][Full Text] [Related]
14. Development of a synthetic cyclized peptide derived from alpha-fetoprotein that prevents the growth of human breast cancer.
Mesfin FB; Andersen TT; Jacobson HI; Zhu S; Bennett JA
J Pept Res; 2001 Sep; 58(3):246-56. PubMed ID: 11576331
[TBL] [Abstract][Full Text] [Related]
15. Contribution of specific amino acid residues within the hFSH alpha 26-46 sequence region to FSH receptor-binding activity.
Cattini-Schultz SV; Stanton PG; Robertson DM; Hearn MT
Pept Res; 1995; 8(4):214-26. PubMed ID: 8527875
[TBL] [Abstract][Full Text] [Related]
16. Potent cyclic monomeric and dimeric peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion based on the Ile-Leu-Asp-Val tetrapeptide.
Dutta AS; Crowther M; Gormley JJ; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Jamieson A; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
J Pept Sci; 2000 Jul; 6(7):321-41. PubMed ID: 10946997
[TBL] [Abstract][Full Text] [Related]
17. Anticancer versus antigrowth activities of three analogs of the growth-inhibitory peptide: relevance to physicochemical properties.
Mizejewski GJ; Eisele L; Maccoll R
Anticancer Res; 2006; 26(4B):3071-6. PubMed ID: 16886636
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial properties of the frog skin peptide, ranatuerin-1 and its [Lys-8]-substituted analog.
Sonnevend A; Knoop FC; Patel M; Pál T; Soto AM; Conlon JM
Peptides; 2004 Jan; 25(1):29-36. PubMed ID: 15003353
[TBL] [Abstract][Full Text] [Related]
19. Review and proposed action of alpha-fetoprotein growth inhibitory peptides as estrogen and cytoskeleton-associated factors.
Mizejewski G; Smith G; Butterstein G
Cell Biol Int; 2004; 28(12):913-33. PubMed ID: 15566961
[TBL] [Abstract][Full Text] [Related]
20. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies.
Cervini LA; Donaldson CJ; Koerber SC; Vale WW; Rivier JE
J Med Chem; 1998 Feb; 41(5):717-27. PubMed ID: 9513600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
